There is limited evidence to support the use of methylphenidate and erythropoietin for the treatment of cancer-related fatigue in some patients, according to a systematic review of randomized controlled trials.
There is limited evidence to support the use of methylphenidate and erythropoietin for the treatment of cancer-related fatigue in some patients, according to a systematic review of randomized controlled trials.